Trimethoprim-sulfamethoxazole resistance in clinical isolates of E. coli from UTI patients in Zaria, Nigeria

Global Medical Microbiology Summit & Expo

November 28-29, 2016 San Francisco, USA

Igwe James Chibueze, Durowiaye T M, Ineke U J, Ekwerekwu I J, Akpa U A, Ehinmidu J O, Olayinka B O and Onaolapo J A

National Biotechnology Development Agency, Nigeria
Ahmadu Bello University, Nigeria
University of Ibadan, Nigeria

Posters & Accepted Abstracts: J Med Microb Diagn

Abstract :

The increasing trend of E. coli resistance to trimethoprim-sulfamethoxazole (TMP-SMZ) among UTI patients is indeed becoming worrisome, as this first class antibiotic of hope in the last few years is becoming ineffective due to resistance associated with emerging and reoccurrence of E. coli infections in UTIs. This study evaluates the resistance pattern of TMP-SMZ resistant E. coli from UTI patients in Zaria, Nigeria using standard microbiological methods. The result showed that out of the 80 suspected E. coli isolates from UTI patients in 4 selected hospitals in Zaria, 68.75% (55) of the isolates were confirmed as E. coli using Macrobat 12E Enterobacteriacea identification kit. Out of which 58.2% (32) were resistant to TMP-SMZ. High resistance profile of the isolates were observed against amoxicillin and cefpirome (96.9%), followed by ceftaxime (78.1), tetracycline (75%), cefpodoxime (68.8), ciprofloxacine and ofloxacin (59.4), chloramphenicol (53.1%), gentamicin (46.9%), aztreonam (31.3%), nitrofurantoin (28.1%) and cetriaxone (21.9%), the most effective antibiotics were observed to be amikacin (3.1) and imipenem (0%). The isolates were observed to have 100% MDR at MARI�0.2. Molecular analysis using PCR showed that dfrXII gene was present in all the 21 (100%) MDR E. coli isolates, 85.7% (18) had sul2 while dfrIa and sul1 genes were absent in all the isolates evaluated in this study. This study showed that high percentage of clinical isolates of E. coli was resistant to TMP-SMZ in Zaria metropolis. Hence, there is the need to re-strategize on the surveillance approach, awareness programmes on antibiotics resistance and dispensing of antibiotics in clinics and community pharmacy in other to curb the resistant trend of bacteria to wide antibacterial spectrum like trimethoprim-sulfamethoxazole (TMPSMZ) among UTI patients in Nigeria.

Biography :

Igwe James Chibueze has completed his PhD in Pharmaceutical Microbiology, MSc in Pharmaceutical Microbiology from Ahmadu Bello University, Zaria, Nigeria) and BSc in Biotechnology from Ebonyi State University, Abakaliki, Ebonyi State. He is currently working as Scientific Officer I (Research Scientist) at the Department of Medical Biotechnology, National Biotechnology Development Agency, Abuja, Nigeria.

Email: igwejames42@yahoo.com